Hollis, Robert L <br/><br/>
Enhanced response rate to pegylated liposomal doxorubicin in high grade serous ovarian carcinomas harbouring BRCA1 and BRCA2 aberrations.  [electronic resource] 

 -  BMC cancer  01 2018 
 - 16 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1471-2407 
<br/><br/><label>Standard No.: </label>10.1186/s12885-017-3981-2  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antibiotics, Antineoplastic--therapeutic use<br/>BRCA1 Protein--genetics<br/>BRCA2 Protein--genetics<br/>Biomarkers, Tumor--genetics<br/>Cystadenocarcinoma, Serous--drug therapy<br/>Doxorubicin--analogs & derivatives<br/>Female<br/>Follow-Up Studies<br/>Genetic Predisposition to Disease<br/>Humans<br/>Middle Aged<br/>Mutation<br/>Neoplasm Grading<br/>Ovarian Neoplasms--drug therapy<br/>Polyethylene Glycols--therapeutic use<br/>Polymorphism, Single Nucleotide<br/>Retrospective Studies<br/>Survival Rate